Literature DB >> 2161816

Cytocidal activity of a synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, and its potentiation of antitumor drugs against multidrug-resistant and sensitive cells in vitro.

H Suzuki1, A Tomida, T Nishimura.   

Abstract

A synthetic isoprenoid, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine (SDB-ethylenediamine), inhibited the colony formation of multidrug-resistant mutant cell lines derived from Chinese hamster V79 (V79/ADM) and human hepatoma PLC/PRF/5 (PLC/COL) cells to a greater extent than that of the parental cells. When combined with other clinically useful antitumor agents, it potentiated the cytotoxic activity of almost all kinds of drugs tested including adriamycin (ADM), actinomycin D, vincristine, cytosine arabinoside, and 5-fluorouracil (5-FU), and the potentiation ratios were higher against V79/ADM cells than against V79/S cells. Among the antitumor agents tested, the activities of bleomycin-group antibiotics were more strongly enhanced by SDB-ethylenediamine and the potentiation was higher in the parental cells than in V79/ADM cells. SDB-ethylenediamine enhanced the uptake of ADM and daunorubicin into V79/ADM and its parental cells, but it did not increase the uptake of 5-FU or peplomycin, indicating that different mechanisms operate for potentiation in the cases of the latter drugs, i.e., not simply an increase of intracellular drug uptake. Two fragments of SDB-ethylenediamine, solanesol (polyprenoid moiety) and the diamine component (verapamil-like moiety), showed neither cytotoxic activity nor potentiator activity, even if they were mixed together, indicating that the steric conformation of intact SDB-ethylenediamine molecule is important for these two activities.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2161816      PMCID: PMC5918030          DOI: 10.1111/j.1349-7006.1990.tb02564.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


N‐solanesyl‐N, N′‐bis(3,4‐dimethoxybenzyl) ethylenediamine adriamycin daunorubicin aclarubicin actinomycin D 5‐fluorouracil 1‐β‐d‐arabinofuranosylcytosine cisplatin methotrexate mitomycin C nimustine vincristine vinblastine bleomycin A2 peplomycin
  15 in total

1.  Resorthiomycin, a novel antitumor antibiotic. I. Taxonomy, isolation and biological activity.

Authors:  H Suzuki; M Tahara; M Takahashi; F Matsumura; T Okabe; A Shimazu; A Hirata; H Yamaki; H Yamaguchi; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1990-02       Impact factor: 2.649

2.  Resorthiomycin, a novel antitumor antibiotic. III. Potentiation of antitumor drugs and its mechanism of action.

Authors:  M Tahara; A Tomida; T Nishimura; H Yamaguchi; H Suzuki
Journal:  J Antibiot (Tokyo)       Date:  1990-02       Impact factor: 2.649

3.  Reversal of multidrug resistance by synthetic isoprenoids in the KB human cancer cell line.

Authors:  M Nakagawa; S Akiyama; T Yamaguchi; N Shiraishi; J Ogata; M Kuwano
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

4.  Effect of bisbenzylisoquinoline (biscoclaurine) alkaloids on multidrug resistance in KB human cancer cells.

Authors:  N Shiraishi; S Akiyama; M Nakagawa; M Kobayashi; M Kuwano
Journal:  Cancer Res       Date:  1987-05-01       Impact factor: 12.701

5.  Mechanism of action of 2-crotonyloxymethyl-4,5,6-trihydroxycyclohex-2-enone, a SH inhibitory antitumor antibiotic, and its effect on drug-resistant neoplastic cells.

Authors:  Y Sugimoto; H Suzuki; H Yamaki; T Nishimura; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1982-09       Impact factor: 2.649

6.  Lactoquinomycin, a novel anticancer antibiotic. II. Physico-chemical properties and structure assignment.

Authors:  T Okabe; K Nomoto; H Funabashi; S Okuda; H Suzuki; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1985-10       Impact factor: 2.649

7.  Cellular uptake and efflux and cytostatic activity of 4'-O-tetrahydropyranyladriamycin in adriamycin-sensitive and resistant tumor cell lines.

Authors:  S Kunimoto; K Miura; K Umezawa; C Z Xu; T Masuda; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1984-12       Impact factor: 2.649

8.  Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

9.  Overcoming drug resistance in cancer cells with synthetic isoprenoids.

Authors:  T Yamaguchi; M Nakagawa; N Shiraishi; T Yoshida; T Kiyosue; M Arita; S Akiyama; M Kuwano
Journal:  J Natl Cancer Inst       Date:  1986-05       Impact factor: 13.506

10.  Potentiation of anticancer agents by new synthetic isoprenoids. II. Inhibition of the growth of transplantable murine tumors.

Authors:  T Yamaguchi; K Ikezaki; T Kishiye; Y Tahara; H Koyama; T Takahasi; H Fukawa; S Komiyama; S Akiyama; M Kuwano
Journal:  J Natl Cancer Inst       Date:  1984-10       Impact factor: 13.506

View more
  4 in total

1.  Molecular dynamics simulation analysis of Focal Adhesive Kinase (FAK) docked with solanesol as an anti-cancer agent.

Authors:  Betty Daneial; Jacob Paul Vazhappilly Joseph; Guruprasad Ramakrishna
Journal:  Bioinformation       Date:  2017-09-30

2.  Novel mechanism of N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine in potentiation of antitumor drug action on multidrug-resistant and sensitive Chinese hamster cells.

Authors:  A Tomida; T Tatsuta; H Suzuki
Journal:  Jpn J Cancer Res       Date:  1991-01

3.  Synergistic effect in culture of bleomycin-group antibiotics and N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, a synthetic isoprenoid.

Authors:  A Tomida; H Suzuki
Journal:  Jpn J Cancer Res       Date:  1990-11

4.  Reversal of P-glycoprotein-mediated paclitaxel resistance by new synthetic isoprenoids in human bladder cancer cell line.

Authors:  Hideki Enokida; Takenari Gotanda; Shoichi Oku; Yoshiharu Imazono; Hiroyuki Kubo; Toshikatsu Hanada; Shigenori Suzuki; Kouhei Inomata; Takao Kishiye; Yoshiyuki Tahara; Kenryu Nishiyama; Masayuki Nakagawa
Journal:  Jpn J Cancer Res       Date:  2002-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.